The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
== Principle == As an analytical biochemistry assay and a "wet lab" technique, ELISA involves detection of an analyte (i.e., the specific substance whose presence is being quantitatively or qualitatively analyzed) in a liquid sample by a method that continues to use liquid reagents during the analysis (i.e., controlled sequence of biochemical reactions that will generate a signal which can be easily quantified and interpreted as a measure of the amount of analyte in the sample) that stays liquid and remains inside a reaction chamber or well needed to keep the reactants contained. This is in contrast to "dry lab" techniques that use dry strips. Even if the sample is liquid (e.g., a measured small drop), the final detection step in "dry" analysis involves reading of a dried strip by methods such as reflectometry and does not need a reaction containment chamber to prevent spillover or mixing between samples. As a heterogenous assay, ELISA separates some components of the analytical reaction mixture by adsorbing certain components onto a solid phase which is physically immobilized. In ELISA, a liquid sample is added onto a stationary solid phase with special binding properties and is followed by multiple liquid reagents that are sequentially added, incubated, and washed, followed by some optical change (e.g., color development by the product of an enzymatic reaction) in the final liquid in the well from which the quantity of the analyte is measured.
== Technology applications == In its earliest form, liquid chromatography was used to separate the pigments of chlorophyll by a Russian botanist. Decades later, other chemists used the procedure for the study of carotins. Liquid chromatography was then used for the isolation of small molecules and organic compounds like amino acids, and most recently has been used in peptide and DNA research. Monolith columns have been instrumental in advancing the field of biomolecular research. In recent trade shows and international meetings for HPLC, interest in column monoliths and biomolecular applications has grown steadily, and this correlation is no coincidence. Monoliths have been shown to possess great potential in the “omics” fields- genomics, proteomics, metabolomics, and pharmacogenomics, among others. The reductionist approach to understanding the chemical pathways of the body and reactions to different stimuli, like drugs, are essential to new waves of healthcare like personalized medicine. Pharmacogenomics studies how responses to pharmaceutical products differ in efficacy and toxicity based on variations in the patient's genome; it is a correlation of drug response to gene expression in a patient. Jeremy K. Nicholson of the Imperial College, London, used a postgenomic viewpoint to understand adverse drug reactions and the molecular basis of human disesase. His group studied gut microbial metabolic profiles and were able to see distinct differences in reactions to drug toxicity and metabolism even among various geographical distributions of the same race.
Mitchell had designed an excellent seaplane for the 1931 Schneider Trophy, but the British government would not fund this excellent design - the Supermarine S.6B, leaving Lucy, Lady Houston, married to Sir Robert Houston, 1st Baronet, to fund the project entirely herself, from a request of the Royal Aero Club; the 230 mph Type 224 led to the 265 mph Type 425, with a 650 hp Goshawk engine; R-R proposed a 27-litre engine, derived from their R engine, in 1934; this new engine led R.J. Mitchell to propose the 350 mph Type 300 with the 1000 hp Merlin engine, and a £10,000 contract was offered for this aircraft to be ready by October 1935; the Hawker Hurricane was a monoplane Hawker Fury; 310 Spitfires were ordered; military historian Corelli Barnett and how later versions of the Spitfire took three times the man hours of the Bf 109; Sir Peter Masefield; 19 Squadron, led by Iliffe Cozens, converted from the Gloster Gauntlet to the Spitfire in August 1938; in the Battle of Britain, thirty Spitfires had the 20mm cannon fitted; the second movement - Fortune plango vulnera of Carmina Burana and the Messerschmitt Bf 109 at RAF Boscombe Down; Spitfire pilot Laddie Lucas; around 350 Spitfires entered US service.
Sources: en.wikipedia.org
=== Nootropic or "smart drug" === Selegiline is considered by some to be a nootropic, otherwise known as a cognitive enhancer or "smart drug", both at clinical and sub-clinical dosages, and has been used off-label and non-medically to improve cognitive performance. It is one of the most popular such agents. Selegiline has been found to have neuroprotective activity against certain neurotoxins and to increase the production of several brain growth factors, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF). The drug has also been found in animal models to improve learning ability and to help preserve it during ischemia and aging. Despite claims that selegiline and other claimed nootropics have cognitive-enhancing effects however, these effects are controversial and their benefits versus risks are uncertain.
22 July – A study proposes polymetallic nodules produce oxygen without light on the abyssal seafloor, with relevance to potential deep sea mining. 29 July – Scientists publish research on the simulation of gravitational waves from a failing warp drive. 30 July A study (19 April) on North Sea oil and gas extraction finds that pollution can spike by more than 10,000% within half a kilometre around offshore drilling sites. The world's first fully automated dental procedure on a human is reported by Boston company Perceptive. Promising results of health and medical research are reported: researchers report an apparent substantially improved prognoses of head and neck cancers if Fusobacterium is present in the patient's oral microbiome, a common bacteria of mouths thought to make bowel cancer worse (6 July), phase 3-trialed lenacapavir for HIV prevention (24 July). Hazard research is published: a study finds electric cars pose a twice as large collision risk to pedestrians in cities than internal combustion engine cars, likely largely due to being quieter (10 July), and a study reports substantial heavy metal contamination of cocoa products (31 July).
In this method, polyvinylpyrrolidone (PVP) is dissolved in water by sonication and mixed with silver colloid particles. Active stirring ensures the PVP has adsorbed to the nanoparticle surface. Centrifuging separates the PVP coated nanoparticles which are then transferred to a solution of ethanol to be centrifuged further and placed in a solution of ammonia, ethanol and Si(OEt4) (TES). Stirring for twelve hours results in the silica shell being formed consisting of a surrounding layer of silicon oxide with an ether linkage available to add functionality. Varying the amount of TES allows for different thicknesses of shells formed. This technique is popular due to the ability to add a variety of functionality to the exposed silica surface.
Sources: en.wikipedia.org
A small N-terminal domain (160 amino-acid residues) A large C-terminal domain (240 amino-acid residues) Each noncovalently-associated monomer subunit consists of both domains. The subunits interact with each other through about 20 hydrogen bonds and four ion pairs, providing stability to the dimer. The two domains in each monomer subunit are more loosely connected, with only six hydrogen bonds and one ion pair between them, and no intra- or intermolecular disulfide bonds. Looking more closely at the two domains, the following structures were described in 1988:
=== October–December 2007: Participatory notes issue === 18,000, 9 October 2007- The SENSEX crossed the 18,000 mark for the first time on 9 October 2007, gaining 788 points, to close at 18,280. The journey from 17,000 to 18,000 took just 8 trading sessions, which is the third fastest 1000-point rise in the history of the SENSEX. 19,000, 15 October 2007- The SENSEX crossed the 19,000 mark for the first time on 15 October 2007, gaining 640 points, to close at 19,059. It took just 4 trading sessions for the SENSEX to move from 18,000 to 19,000. This is the fastest 1000-point rise ever for the index. In addition, the rise from 16,000 to 19,000 in 17 trading sessions sets a record for the fastest 3,000-point rally in the history of the SENSEX. On 16 October 2007, SEBI (Securities & Exchange Board of India) proposed curbs on participatory notes which accounted for roughly 50% of FII investment in 2007. SEBI was not happy with P-notes because it was not possible to know who owned the underlying securities, and hedge funds acting through P-notes might therefore cause volatility in the Indian markets. However the proposals of SEBI were not clear and this led to a knee-jerk crash when the markets opened on the following day (17 October 2007). Within a minute of opening trade, the SENSEX crashed by 1,744 points or about 9% of its value – the biggest intra-day fall in Indian stock markets in absolute terms until then. This led to the automatic suspension of trade for one hour. Finance Minister P.
In static solution culture, plants are grown in containers of nutrient solution, such as glass Mason jars (typically, in-home applications), pots, buckets, tubs, or tanks. The solution is usually gently aerated but may be un-aerated. If un-aerated, the solution level is kept low enough that enough roots are above the solution so they get adequate oxygen. A hole is cut (or drilled) in the top of the reservoir for each plant; if it is a jar or tub, it may be its lid, but otherwise, cardboard, foil, paper, wood or metal may be put on top. A single reservoir can be dedicated to a single plant, or to various plants. Reservoir size can be increased as plant size increases. A home-made system can be constructed from food containers or glass canning jars with aeration provided by an aquarium pump, aquarium airline tubing, aquarium valves or even a biofilm of green algae on the glass, through photosynthesis. Clear containers can also be covered with aluminium foil, butcher paper, black plastic, or other material to eliminate the effects of negative phototropism. The nutrient solution is changed either on a schedule, such as once per week, or when the concentration drops below a certain level as determined with an electrical conductivity meter. Whenever the solution is depleted below a certain level, either water or fresh nutrient solution is added. A Mariotte's bottle, or a float valve, can be used to automatically maintain the solution level. In raft solution culture, plants are placed in a sheet of buoyant plastic that is floated on the surface of the nutrient solution.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.